The North Lanarkshire Collaborative Research Organisation (CRO), RoukenBio, has announced a strategic partnership with AVS Bio, a global biologics solution provider, to enable more informed candidate selection.
The collaboration integrates AVS Bio’s comprehensive antibody discovery and development services with RoukenBio’s expertise in mechanism-driven functional characterisation of biologics using advanced cell-based and primary cell assay systems.
Integrated antibody discovery and functional assessment
By aligning antibody discovery and optimisation with early, rigorous functional assessment, the collaboration enables biotherapeutic developers to access an integrated workflow in which prioritised candidates are seamlessly transitioned into functional cell-based and primary immune cell assays. This allows early interrogation of biological activity, pathway modulation, and context-dependent effects that are often not captured by binding or biochemical assays alone.
The partnership aims to improve lead candidate prioritisation and reduce translational uncertainty, by introducing physiologically relevant functional data earlier in development, addressing a key driver of late-stage failure: the advancement of antibodies with incomplete or misleading mechanistic understanding into preclinical and clinical development.
RoukenBio’s expertise in immune-mediated disease biology
“Too many antibody programmes fail not because of poor discovery, but because candidates are advanced without a sufficiently rigorous understanding of the mechanism of action in relevant immune cell contexts,” said Adele Hannigan, Chief Business Officer at RoukenBio. “RoukenBio is deliberately specialised in biotherapeutics for immune-mediated disease biology, where context-dependent functional behaviour is critical.
“By partnering with AVS Bio, we are integrating high-quality antibody discovery with early, mechanism-driven functional characterisation in complex and primary immune cell systems, enabling more informed candidate selection and materially reducing translational risk before programmes enter IND-enabling development.”
AVS Bio’s perspective on enhanced antibody discovery
“Diversity, not only from a sequence perspective, but also regarding epitope landscape and functionality, is a key contributor to successful therapeutic antibody generation, ensuring the prioritisation of the best-performing molecule for clinical development. Combining AVS Bio’s excellence in diversity-driven antibody discovery and optimisation with RoukenBio’s expertise in translational-relevant functional profiling strongly strengthens our data-driven decision-making approach in therapeutic antibody generation,” emphasised Ilse Roodink, Chief Scientific Officer at AVS Bio.
“We are excited to partner with RoukenBio to enhance data-driven lead antibody selection through early, mechanism-focused functional insights, ultimately enabling our customers and partners to make better-informed decisions throughout their therapeutic antibody development journey.”
RoukenBio and AVS Bio: A more predictive pathway toward IND‑enabling studies
The partnership reflects a shared scientific philosophy that successful antibody therapeutics require not only high-quality discovery and optimisation, but also early, mechanism-driven validation of functional activity in relevant biological systems. By integrating antibody discovery and optimisation with robust functional characterisation, RoukenBio and AVS Bio aim to provide biotherapeutic developers with a more predictive, decision-driven pathway from initial antibody discovery through IND-enabling studies and entry into the clinic.
